- Home
- NVS vs MRK Comparison
NVS vs MRK Comparison
Compare NVS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | MRK |
|---|---|---|
| Founded | 1895 | 2000 |
| Country | Switzerland | United States |
| Employees | 75267 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.9B | 268.7B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | NVS | MRK |
|---|---|---|
| Price | $151.24 | $118.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $144.00 | $124.38 |
| AVG Volume (30 Days) | 1.8M | ★ 6.4M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | 2.02% | ★ 2.81% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $2.34 | $3.73 |
| Revenue Next Year | $5.14 | $5.42 |
| P/E Ratio | $23.13 | ★ $16.58 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $97.72 | $75.40 |
| 52 Week High | $170.46 | $125.14 |
Technical Indicators
Market Signals| Indicator | NVS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 50.23 |
| Support Level | $145.30 | $113.27 |
| Resistance Level | $158.80 | $125.14 |
| Average True Range (ATR) | 2.19 | 2.42 |
| MACD | 0.32 | 0.27 |
| Stochastic Oscillator | 52.34 | 57.39 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).